POSTER: CT-235 Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)